Emerging drugs for the treatment of metastatic renal cancer. (Q36989925)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Emerging drugs for the treatment of metastatic renal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

Nicholas J. Vogelzang

series ordinal

2

object named as

Nicholas J Vogelzang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

605-618

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Signal-transduction inhibitors in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Exelixis: Integrated Drug-Discovery and Development Platform for Human Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Accessing the Exelixis collection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Tumor angiogenesis: cause or consequence of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5dione (1) as a Highly Selective VEGF-R2/3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.4.605

10.1517/14728214.12.4.605

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17979602 AND SRC:MED&resulttype=core&format=json

9 January 2020

1 reference